This was a good PR - basket trial approval is good. It is a 30 patient study and as usual NP is too excited to say that enrollment can be completed in 60 days - it takes that much time to get a new site ready for enrollment.
Anyways - this is a good progress and if not 60, we can see enrollment in 90-100 days which is much faster than most trials.
Another advantage - this is open label so NP can jump and issue a new PR with few more patients being enrolled and some patients showing better results.
Am I the only one in awe of the results for the first patient (let alone the rest of them)? You’re talking about people that would be dead right now had it not been for Leronlimab.
News 
Market Data 
Discover 
AI
